News : drug development

Leading contract research provider, Syntagon, is delighted to announce that it has entered into a collaborative agreement with world-class Quality Assurance (QA) expert George Köllner.
George brings with him more than 20 years’ experience from the pharma industry. He has served as Director of Quality Assurance at AstraZeneca where he led the development and implementation of modern Quality Assurance systems in...

Leading contract research provider, Syntagon, is set to implement a restructuring programme designed to further improve its offering to customers in the field of drug substance development.
Syntagon’s Sweden-based operations (Syntagon AB) will focus and strengthen its customer-oriented expertise within drug substance development, quality assurance and regulatory support, while the Group’s Latvian site (SIA...

Leading contract research organisation, Syntagon, has unveiled important changes to its management team. With immediate effect, Dr. Andis Slaitas will replace Dr. Michael Lofthagen as Syntagon CEO.
Andis has been with Syntagon since 2005 and has been instrumental in developing the Syntagon Baltic site, based in Latvia, into a world-class chemistry facility. Prior to his new position, Andis was VP of operations...

Ponsus Pharma signs a product distribution agreement with Celsus EHF for Proderm Sunscreen in Sweden, Iceland and Norway.
STOCKHOLM, May. 11. Ponsus Pharma has signed a product distribution agreement with Celsus EHF to distribute Proderm® Sunscreen in Sweden, Iceland and Norway. Proderm Sunscreen is today available in a SPF6, SPF20 and a SPF30 version. This distribution agreement will make Proderm Sunscreen...

Cosmetically elegant, non-comedogenic cream formulation for easier application to smaller surface areas
STOCKHOLM. Ponsus Pharma announces the introduction of a cosmetically elegant cream formulation using the patented PRODERM TECHNOLOGY®. The introduction of the cream formulation is a strategic line extension to the earlier launched and successfully marketed foam formulation.
PRODERM TECHNOLOGY is...

Leading contract research organisation, Syntagon, has unveiled a strategic pricing initiative that will see substantial cost savings for biotechnology and pharmaceutical customers taking compounds into phase I and phase II clinical trials.
“Now, more than ever, customers are under growing pressure to make their limited resources stretch further. Cost-efficiency is increasingly critical; and maintaining cash is...

Ponsus Pharma signs an exclusive product distribution agreement with Vitaflo Scandinavia AB for Proderm Hud in Sweden, Denmark, Finland and Norway
STOCKHOLM, Jan. 27. Ponsus Pharma has signed an exclusive distribution agreement with Vitaflo Scandinavia AB to distribute Proderm® Hud in Sweden, Denmark, Finland and Norway to further strengthen Vitaflo Scandinavia AB’s strong portfolio of dermatological...